Ultragenyx Pharmaceutical Inc. 8-K

What Happened

• On January 30, 2026 Ultragenyx Pharmaceutical Inc. (RARE) filed an 8-K and issued a press release announcing it resubmitted its Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA).
• The resubmission includes substantial longer-term clinical data (an additional year of follow-up), cerebrospinal fluid (CSF) heparan sulfate and other biomarker data, and comprehensive responses to chemistry, manufacturing, and controls (CMC) observations noted in a Complete Response Letter (CRL) issued in July 2025. The FDA previously granted Priority Review for UX111 in February 2025.

Key Details

• Filing date: 8-K filed January 30, 2026; resubmission to FDA on that date.
• Regulatory timing: Company expects a PDUFA action date to be assigned within a month of resubmission and anticipates up to a six-month review, targeting a PDUFA date in Q3 2026.
• Data highlights: Resubmitted BLA includes additional long-term clinical follow-up showing durable treatment effects across multiple biomarkers and continued clinical separation from natural history, with an acceptable safety profile.
• Next public update: Detailed updates to be presented at WORLDSymposium™ 2026 in San Diego (scheduled the week after the filing).

Why It Matters

• For investors, this is a key regulatory milestone: a resubmitted BLA with added long-term efficacy, biomarker, and CMC responses moves UX111 closer to a potential FDA decision. If approved, UX111 would be the first approved therapy for Sanfilippo syndrome type A (MPS IIIA), which could materially affect Ultragenyx’s clinical and commercial prospects.
• The company also reiterated standard forward-looking risk disclosures noting uncertainties in regulatory review, manufacturing, third-party reliance, safety, timing, and other risks that could affect outcomes.